{"id":758384,"date":"2023-05-12T06:36:31","date_gmt":"2023-05-12T10:36:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\/"},"modified":"2023-05-12T06:36:31","modified_gmt":"2023-05-12T10:36:31","slug":"reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\/","title":{"rendered":"Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CUPERTINO, Calif., May  12, 2023  (GLOBE NEWSWIRE) &#8212; Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (\u201cReviva\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, today announced that it will be participating in the Lytham Partners Spring 2023 Investor Conference taking place virtually on Thursday, May 18, 2023.<\/p>\n<p>\n        <strong>Company Webcast<\/strong>\n      <\/p>\n<p>The Company\u2019s webcasted presentation will be available for viewing at 9:00am ET on Thursday, May 18, 2023, on the Company&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=E5Udp1BbfcZINGpmwStA6_sGhX9XrQfIqnUYRYYG2cj5N0-CAkvGIHJv1hHURc-jsY6sIfCw0fPiAHe-pCsdjb_DZ_9Wn9LVcj5MmvUOPLTJWZSzVm0Fh3lZvaCP0bBx\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/revivapharma.com\/events\/<\/a> or at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=E5Udp1BbfcZINGpmwStA6-e3zWoTbP1H0rOgLAvPr7iWx1ILUE2ZYZHOEibRbTf04TxEqn4wiQlZtZQNAGjN_LSFEK2Qxk3Hb6vEzWiWdpdHXTacjE23OE3OwxhCtFCnVGsCSd40278gy24dMxLcQQ==\" rel=\"nofollow noopener\" target=\"_blank\"><u>https:\/\/wsw.com\/webcast\/lytham8\/rvph\/2066400<\/u><\/a> The webcast will also be archived and available for replay.<\/p>\n<p>\n        <strong>Industry Panel<\/strong>\n      <\/p>\n<p>Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be participating on a panel titled Phase 3 Drugs to Watch. The panel will be webcasted on Thursday, May 18, 2023, at 2:00pm ET on the Company&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=E5Udp1BbfcZINGpmwStA6_sGhX9XrQfIqnUYRYYG2cgfQlIwIODc2I11RDiwl7VN11-uZzvWP0SbpVoBfTUFFT16zXSE3Ny7HOHybDrlHV7gWg4nfReidHeqIAAyhKV-\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/revivapharma.com\/events\/<\/a> or at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=E5Udp1BbfcZINGpmwStA6-e3zWoTbP1H0rOgLAvPr7gWFLsfdqc3v5HuZpgDhfjLA3-CGBoVzUtxR09Q7txd6zyNwFsOcyB2U4GNdCcYaqy3wF12ck-qu_RQIVTnZIDrMGRDcHbFGfewcjnCxEm5LfZ8dV5x7j8vlQUYLPq082E=\" rel=\"nofollow noopener\" target=\"_blank\"><u>https:\/\/wsw.com\/webcast\/lytham8\/panel3\/2272725<\/u><\/a>. The webcast will also be archived and available for replay.<\/p>\n<p>\n        <strong>1&#215;1 Meetings<\/strong>\n      <\/p>\n<p>Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j8gvhpDXq8wWyc0ZsFirYUxWQBI0l-q-AZXvII9t0n6yRmnJGy_j4YopeyN9SMChm5AplaIVHsO7ox574urrl8mKku0s2fU1i024Xzo37lE=\" rel=\"nofollow noopener\" target=\"_blank\">1&#215;1@lythampartners.com<\/a> or register at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=E5Udp1BbfcZINGpmwStA61jLYH5c2ry49W4eqzSo9LxoPcGxJinMTOulA2PMdTdMP22nBf94cRIztpxyetXsvdpG_9KDZnTO8EPSzAYhQ07TcEnQ3pzg2vh8S233RRdWKBBcqpQIG1klGbtCIa7VZBAXCSPPVc0EB7nf3lo3Y6A=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.lythampartners.com\/spring2023invreg\/<\/a>. <\/p>\n<p>\n        <strong>About Reviva\u2019s Lead Drug Candidate Brilaroxazine\u00a0<\/strong><br \/>\n        <br \/>Brilaroxazine is a new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors implicated in schizophrenia and its comorbid symptoms. In a multinational, multicenter, double-blind Phase 2 study in 234 patients with acute schizophrenia or schizoaffective disorder, brilaroxazine\u00a0met its primary endpoint, reducing Positive and Negative Syndrome Scale (PANSS) total score and demonstrating statistically significant improvement of overall drug treatment outcomes using Clinical Global Impression (CGI) scale and for secondary endpoints evaluating social functioning, and positive and negative symptoms, and directional improvements for depression and cognition. In this completed Phase 2 study, brilaroxazine met all safety endpoints with no weight gain, no increase in blood sugar and lipids, and no cardiac or endocrine adverse effects compared to placebo. Positive data from a clinical drug-drug interaction (DDI) study investigating the potential effect of CYP3A4 enzyme on brilaroxazine in healthy subjects supports no clinically significant interaction when combined with a CYP3A4 inhibitor. A full battery of regulatory compliant toxicology and safety pharmacology studies has been completed for brilaroxazine. The U.S. Food and Drug Administration (FDA) has agreed to consider a potential superior safety label claim if there is a positive outcome on a relevant endpoint in a pivotal Phase 3 study in patients with schizophrenia. Reviva intends to develop brilaroxazine\u00a0for other neuropsychiatric indications including bipolar disorder, major depressive disorder (MDD) and attention-deficit\/hyperactivity disorder (ADHD).<\/p>\n<p>Additionally, brilaroxazine\u00a0has shown promising efficacy for pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF) with mitigation of lung fibrosis and inflammation in translational animal models. Reviva believes brilaroxazine has the potential to delay disease progression in PAH and IPF and intends to develop brilaroxazine for these pulmonary indications. Brilaroxazine\u00a0has already received Orphan Drug Designation by the U.S. FDA for the treatment of these conditions.<\/p>\n<p>To learn more about the clinical and preclinical data available for brilaroxazine, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PXQnXJlCCXzqviRcmXyjZ-PljyrUeJ9GCuc-vML0SBEHGdDAIg1XyEO9Xs-7-rjlyR6YeZ-R6f8afUoWz1JK3xIT92WNw13C3-SUpD3Ecn5xi4OD54vChyOMEbnAzystnvoOVM9dd_vYub9BC206Ft1gMGGjclmabHGIJT3vwT1et7ZcUNSTGECjug5li1Txsyv_6AV5ARs9aWfJiTL08RGXYBKM5Yxv6b_0RI7wFM9Nb6p0r8eMM2t_XAk93fkFfK6JglmuSsz-UU_TFcSGS31lRe8Fgdf2k0nR8bkHkKc=\" rel=\"nofollow noopener\" target=\"_blank\">revivapharma.com\/publications<\/a>.<\/p>\n<p>\n        <strong>About Reviva\u00a0<\/strong><br \/>\n        <br \/>Reviva is a clinical-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva\u2019s current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva\u2019s pipeline currently includes two drug candidates, brilaroxazine and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine\u00a0and RP1208 in the United States (U.S.), Europe, and several other countries.<\/p>\n<p>\n        <strong>Corporate Contact:<\/strong><br \/>\n        <br \/>Reviva Pharmaceuticals Holdings, Inc.<br \/>Laxminarayan Bhat, PhD\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1eN_0n0GnlS2ZInnUjJYYQHozAX3vo3JGzUsM3b6WeAGT9nBTxquaoNJRGmhnFpvL9qUhWA0OkjLx-tkQ8d7STVxwINfvTZilpHm2hjFUQA=\" rel=\"nofollow noopener\" target=\"_blank\">www.revivapharma.com<\/a><\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>LifeSci Advisors, LLC<br \/>Bruce Mackle<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=p9jOVtNAVOdvozoHElfEGfhDqZUWMqR_HNSu7ACeMx61OlL2YBZAkc_IXXIWmE6OfyJqBJN0bOw6_QMuwohQcradnhKKWsWimYhhN22Fuwg2ASC2bPG85W4ObMi9vGKKjd4Vxrk3d5_UQvQlLcxuM6dVYLXLfMGkLVHx3EoAwg__DekzUBJNwm95xJE0jsidWOdyqDFq_xNXPm48wXXjzVew15VycDUL33ds6-bUaXmeuC4vre14valdlAWfCUcvAQpA68NmKk09QEy3YrKBw3YHTln6z6UctaFILDAs9v4=\" rel=\"nofollow noopener\" target=\"_blank\">bmackle@lifesciadvisors.com<\/a><\/p>\n<p>Lytham Partners, LLC<br \/>Ben Shamsian\u00a0CPA<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nzVNDWJ_k3nAr9iBHZYp9FicrmFuoL8O0MhXtt0_oSotP-qDXTzUPmDk612oMz4PzFyN8jkY0dVXDnqL6eXe14PXXsa64e1bJC8sAYT27He0DUnRa2hfHwbQOGf9Y4jK\" rel=\"nofollow noopener\" target=\"_blank\">shamsian@lythampartners.com<\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzAyNyM1NTg3NDA5IzUwMDA3NTM4MQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NzY5YmNmZjctMGRjOC00Y2NmLWI4ZTItYWQxMGNjNTA5ZjdhLTUwMDA3NTM4MQ==\/tiny\/Reviva-Pharmaceuticals.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CUPERTINO, Calif., May 12, 2023 (GLOBE NEWSWIRE) &#8212; Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (\u201cReviva\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, today announced that it will be participating in the Lytham Partners Spring 2023 Investor Conference taking place virtually on Thursday, May 18, 2023. Company Webcast The Company\u2019s webcasted presentation will be available for viewing at 9:00am ET on Thursday, May 18, 2023, on the Company&#8217;s website at https:\/\/revivapharma.com\/events\/ or at https:\/\/wsw.com\/webcast\/lytham8\/rvph\/2066400 The webcast will also be archived and available for replay. Industry Panel Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be participating on a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-758384","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CUPERTINO, Calif., May 12, 2023 (GLOBE NEWSWIRE) &#8212; Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (\u201cReviva\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, today announced that it will be participating in the Lytham Partners Spring 2023 Investor Conference taking place virtually on Thursday, May 18, 2023. Company Webcast The Company\u2019s webcasted presentation will be available for viewing at 9:00am ET on Thursday, May 18, 2023, on the Company&#8217;s website at https:\/\/revivapharma.com\/events\/ or at https:\/\/wsw.com\/webcast\/lytham8\/rvph\/2066400 The webcast will also be archived and available for replay. Industry Panel Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be participating on a &hellip; Continue reading &quot;Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-12T10:36:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzAyNyM1NTg3NDA5IzUwMDA3NTM4MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference\",\"datePublished\":\"2023-05-12T10:36:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\\\/\"},\"wordCount\":650,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNzAyNyM1NTg3NDA5IzUwMDA3NTM4MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\\\/\",\"name\":\"Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNzAyNyM1NTg3NDA5IzUwMDA3NTM4MQ==\",\"datePublished\":\"2023-05-12T10:36:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNzAyNyM1NTg3NDA5IzUwMDA3NTM4MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNzAyNyM1NTg3NDA5IzUwMDA3NTM4MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference - Market Newsdesk","og_description":"CUPERTINO, Calif., May 12, 2023 (GLOBE NEWSWIRE) &#8212; Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (\u201cReviva\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, today announced that it will be participating in the Lytham Partners Spring 2023 Investor Conference taking place virtually on Thursday, May 18, 2023. Company Webcast The Company\u2019s webcasted presentation will be available for viewing at 9:00am ET on Thursday, May 18, 2023, on the Company&#8217;s website at https:\/\/revivapharma.com\/events\/ or at https:\/\/wsw.com\/webcast\/lytham8\/rvph\/2066400 The webcast will also be archived and available for replay. Industry Panel Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be participating on a &hellip; Continue reading \"Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-12T10:36:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzAyNyM1NTg3NDA5IzUwMDA3NTM4MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference","datePublished":"2023-05-12T10:36:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\/"},"wordCount":650,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzAyNyM1NTg3NDA5IzUwMDA3NTM4MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\/","name":"Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzAyNyM1NTg3NDA5IzUwMDA3NTM4MQ==","datePublished":"2023-05-12T10:36:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzAyNyM1NTg3NDA5IzUwMDA3NTM4MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzAyNyM1NTg3NDA5IzUwMDA3NTM4MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/758384","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=758384"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/758384\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=758384"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=758384"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=758384"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}